Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma

Sarcomas are rare tumors with generally poor prognosis, for which current therapies have shown limited efficacy. Histone deacetylase inhibitors (HDACi) are emerging anti-tumor agents; however, little is known about their effect in sarcomas. By using established and patient-derived sarcoma cells with...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncogenesis
Main Authors: Di Martile, Marta, Desideri, Marianna, Tupone, Maria Grazia, Buglioni, Simonetta, Antoniani, Barbara, Mastroiorio, Carlotta, Falcioni, Rita, Ferraresi, Virginia, Baldini, Nicola, Biagini, Roberto, Milella, Michele, Trisciuoglio, Daniela, Del Bufalo, Donatella
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group UK 2018
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833676/
https://ncbi.nlm.nih.gov/pubmed/29472530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0026-x
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים